Healthcare News and Headlines
Healthcare News and Headlines
Insmed announced that a Phase 3 trial showed adding its inhaled antibiotic Arikayce to standard therapy significantly improved respiratory symptoms and boosted culture conversion rates in patients with newly diagnosed mycobacterium avium complex (MAC) lung infection. The study met its primary efficacy endpoints, confirming benefit in antibiotic‑naïve patients. Arikayce, which received accelerated approval in 2018 for advanced, treatment‑refractory MAC, could now seek label expansion for earlier‑stage disease. The data positions Insmed for higher sales and broader market reach.
The Independent Budget Office report shows Staten Island achieved the fastest advanced life support (ALS) EMS response in New York City in 2024, with 82% of calls answered within ten minutes. Across all boroughs, response times have slipped over the...
Avalo Therapeutics announced its 2025 financial results, reporting $98.3 million in cash and short‑term investments that should fund operations into 2028. Research and development expenses jumped to $50.1 million, driven by the Phase 2 LOTUS trial of abdakibart (AVTX‑009) for hidradenitis suppurativa. The...
Daymark Health, a Philadelphia‑based cancer‑care platform, announced the creation of a Clinical Advisory Board to steer its value‑based, full‑risk care strategy. The board brings together leading oncologists, health‑policy experts, patient advocates and former government officials, including Dr. Ezekiel Emanuel and...
Pfizer and Valneva’s experimental Lyme vaccine cut the risk of infection by more than 70% in a late‑stage trial, offering a promising preventive tool for a disease that affects roughly 476,000 Americans annually. The study, however, missed its primary statistical...
Apogee Therapeutics reported that its experimental long‑acting eczema biologic, zumilokibart, achieved sustained skin‑clearance in a mid‑stage trial. Seventy‑five percent of patients receiving the drug every three months and 85 % of those dosed every six months maintained an EASI‑75 response after...
IntraBio has filed a supplemental New Drug Application (sNDA) with the U.S. FDA seeking approval of Aqneursa (levacetylleucine) for Ataxia‑Telangiectasia (A‑T). The filing is supported by a Phase III trial that met its primary and key secondary endpoints and demonstrated a...
Serial entrepreneur Martin Varsavsky is launching Certuma, a startup aiming to create the first FDA‑approved AI doctor. The company raised $10 million in seed funding at a $60 million valuation and is targeting 25 low‑risk conditions such as UTIs and sore throats....
Recent research highlights three critical fronts in hospice and palliative care: a Community Hospice and Palliative Medicine (CHPM) fellowship at the University of Colorado is boosting mid‑career physicians' skills and confidence to address national workforce shortages; the Canadian PEACH program...
PointClickCare unveiled a next‑generation electronic health record tailored for practice groups, tightly integrated with its flagship post‑acute care platform used by over 30,000 organizations. The solution embeds AI‑driven Ambient Scribe and clinical risk insights directly into physician workflows, promising measurable...
Resmed’s sixth Global Sleep Survey of 30,000 respondents across 13 countries shows that 53% now rank sleep as the most important health behavior, ahead of diet and exercise. Yet more than half of participants report getting quality sleep only four...
Britain’s mid‑life adults (30‑59) now account for 56% of all private diagnostic scans, a six‑fold increase since 2022, driven largely by chronic pain and preventive health concerns. With NHS waiting lists exceeding two million and delays over six weeks, private...
A Dallas federal jury convicted former NFL player Keith J. Gray of orchestrating a $328 million Medicare fraud scheme that billed for unnecessary cardiovascular genetic tests. Gray, who owned Axis Professional Labs and Kingdom Health Laboratory, was found guilty of conspiracy,...
Voters who cite affordability as their top worry are overwhelmingly pointing to health‑care costs, according to recent polling. The trend has prompted Democrats to reframe their health‑care narrative around price rather than access, using the issue to energize their base....
Benjamin Landa, a nursing‑home owner nominated by Donald Trump for U.S. ambassador to Hungary, is facing a lawsuit from his own facility, Pinnacle Multicare Nursing and Rehabilitation Center, which seeks to block a HHS audit that identified at least $31.2 million...
Life‑sciences firms are confronting compressed validation timelines, tighter regulatory oversight and fragile supply chains, prompting a shift from cost‑driven to confidence‑driven site selection. Middlesex County, New Jersey, offers that confidence through a highly educated talent pool, continuous university‑backed research, and deep...
Even with dental insurance, many Americans still face sizable out‑of‑pocket bills. The article follows 65‑year‑old Russell Anthony, who expects to spend about $2,000 on dental care despite having coverage, illustrating the common "100/80/50" rule and annual benefit caps of $1,000‑$2,000....
ProPublica has upgraded its Nursing Home Inspect database with a searchable owner, manager, and officer function, letting users trace ownership across more than 14,000 facilities. The new tool reveals that a single individual can be linked to over 100 nursing...
HUTCHMED has launched a Phase III trial of HMPL‑760 combined with R‑GemOx in relapsed/refractory diffuse large B‑cell lymphoma (DLBCL) patients in China, dosing the first patient on March 20, 2026. The study will enroll approximately 240 patients who have failed first‑line therapy and...
Researchers introduced a yolk–shell BFO@tBT‑C nanoparticle that exploits shear stress at clot sites to trigger coupled tribo‑ and piezoelectric effects, generating reactive oxygen species for thrombolysis. The dynamic p–n heterojunction yields potentials 3.6‑ and 2.1‑fold higher than isolated triboelectric or...
Dizal announced topline results from its Phase 3 WU‑KONG28 trial, comparing oral once‑daily Zegfrovy (sunvozertinib) to platinum‑based chemotherapy as first‑line treatment for advanced NSCLC with EGFR exon 20 insertion mutations. The study met its primary endpoint, demonstrating a statistically significant improvement in...
U.S. weight‑loss drugmakers are slashing GLP‑1 prices to win cash‑pay customers as insurers balk at coverage. Eli Lilly reduced Zepbound’s monthly cost by $50‑$100, bringing it to $299, while Wegovy now sells for $149 a month, far below its $1,600 launch...
A secondary analysis of the multicenter NEED trial found that feeding intolerance (FI) in critically ill patients receiving early enteral nutrition was linked to higher 28‑day mortality after multivariable adjustment (adjusted OR 1.37). FI also resulted in longer ICU stays, fewer...
The study surveyed 88 registered dietitians in Saudi Arabia to assess attitudes and readiness for personalized nutrition (PN) and multi‑omics technologies. Adoption of PN technologies was low at 16%, with work experience showing a modest positive correlation to perceived usefulness,...
Researchers evaluated nutritional status in 113 Chinese Huntington’s disease patients using CONUT, GNRI, and PNI scores and compared them with matched healthy controls. Malnutrition was markedly more common in HD, especially by CONUT (34.5% vs 13.3%) and GNRI (8% vs...
A Korean stroke registry of 1,484 acute ischemic stroke patients examined whether the C‑reactive protein‑to‑albumin ratio (CAR) and the CRP‑triglyceride‑glucose index (CTI) predict 90‑day functional outcomes. After multivariable adjustment, higher CAR (OR 1.25) and higher CTI (OR 1.38) were independently associated with...
Induced pluripotent stem cells (iPSCs) are being engineered into diverse therapeutic cell types, while in vivo reprogramming aims to convert resident cells directly within patients, eliminating traditional cell‑manufacturing steps. Both strategies depend on precise recombinant growth factors, cytokines, extracellular matrix proteins...
Researchers Cheng, Zhi and Midgley have unveiled reinforced biotubes—bioengineered vascular grafts that combine living cells with nanofibrous reinforcement—to address durability and availability limits of current grafts. The tubes are fabricated in bioreactors, seeded with smooth‑muscle and endothelial progenitor cells, and...
Gene‑therapy candidates for hereditary hearing loss are gaining traction as safety concerns ease with localized delivery. Regeneron’s DB‑OTO and Eli Lilly’s AK‑OTOF have each demonstrated clinically meaningful hearing improvements in early‑stage trials, positioning them as frontrunners for the first approved deafness...
Sue Chapman Moss, Bayada’s senior vice president of payer strategy and new executive director of Hearts for Home Care, warned that state Medicaid reimbursement is tightening after the One Big Beautiful Bill, pressuring home‑based providers with lower rates and reduced...
Knee replacement remains one of the most common orthopaedic procedures, with roughly 800,000 surgeries performed annually in the United States. Advances such as cementless implants, robotics and refined soft‑tissue balancing have improved precision and reduced recovery time, making about half...
Chinese researchers unveiled the YDHB‑NS01 cerebrovascular intervention robot, which cuts brain angiography time by roughly 29%, shaving nine minutes off a standard 38‑minute procedure. In a head‑to‑head trial at Peking Union Medical College Hospital, the robot matched manual methods with...
Elpida, an AI‑driven marketing compliance platform for healthcare, launched today to address the growing friction of manual content reviews. The FDA’s new generative‑AI enforcement tool has spiked warning letters by 73%, highlighting the urgency for automated safeguards. Elpida’s "Live Regulatory...
The FDA’s National Priority Voucher (CNPV) program, launched in June 2025, promises to cut drug review times from 10‑12 months to just one or two months for products that meet defined national priorities. Early successes include Johnson & Johnson’s Tecvayli/Darzalex...
Remedy Place, a boutique wellness club with locations in Los Angeles, New York and Boston, has introduced a $500 smart NAD injection pen that lasts 30 days and is reusable with a fresh needle for each dose. The pen is manufactured by UK‑based...
University of Auckland researchers have identified the lateral parafacial region of the brainstem as a hidden driver of neurogenic hypertension, linking forced exhalations to sympathetic nerve activation. In animal models, silencing this nucleus normalized blood pressure, confirming a causal link...
Scotland has become the first UK nation to add spinal muscular atrophy (SMA) to its universal newborn heel‑prick screening, rolling it out to all babies as part of a two‑year pilot. The program will test roughly 50,000 infants annually, identifying...
Malaysia’s Health Ministry, together with the Attorney‑General’s Chambers and other agencies, will represent the country at the sixth Intergovernmental Working Group (IGWG6) negotiations on pandemic preparedness, held March 23‑28 at WHO headquarters in Geneva. The delegation will participate virtually, a decision...
Dental costs deter roughly 30% of Australian adults and nearly half of New Zealanders from seeking care, prompting many to question recommended restorations. Fillings, crowns and implants each have distinct longevity—5‑15 years for composites, 10‑15 years for crowns, and decades for implants with...
Researchers introduced K‑4, a novel AMPA‑receptor positive allosteric modulator, which produced rapid and sustained antidepressant‑like effects in treatment‑resistant depression rat models. Bulk RNA‑seq revealed that K‑4 markedly down‑regulated NADPH oxidase‑1 (NOX‑1) in the medial prefrontal cortex and lateral habenula. Pharmacological...
Romania’s 1966 Decree 770 sharply restricted abortions, causing births to double and maternal mortality to surge by nearly 150 % over the next two decades. Illegal, unsafe procedures accounted for more than 80 % of those deaths, with an estimated 10,000 women dying...
Australian lawmakers in Queensland and the Northern Territory have moved to prohibit public‑system doctors from prescribing gender‑affirming medication to new trans patients under 18, while allowing those already in care to continue treatment. The changes arrive amid a global reassessment...
Australian researchers examined whether people with moderate‑to‑severe cannabis use disorder (CUD) display an attentional bias toward cannabis images. Using a visual‑probe task with 108 participants, they found no overall bias compared with controls. Within the CUD group, only a marginally...
Harvard gastroenterologist Dr. Trisha Pasricha explained that normal bowel habits can vary widely, with frequency ranging from once daily to once every three days depending on diet, fiber, and lifestyle. She warned that spending more than five minutes on the...
The FDA issued a Drug Safety Communication clarifying that citalopram (Celexa) should not be prescribed above 40 mg daily because higher doses significantly prolong the QT interval and can trigger fatal Torsade de Pointes. The label now mandates a maximum of...
The FDA has updated labels for drospirenone‑containing oral contraceptives after reviewing epidemiologic studies that suggest a potentially higher risk of venous thromboembolism compared with other progestins. The new warnings note that some studies report up to a three‑fold increase in...
The FDA issued a drug safety communication on April 20, 2012, adding a contraindication for aliskiren‑containing antihypertensives when combined with ACE inhibitors or ARBs in patients with diabetes, and a warning for those with moderate to severe renal impairment. The...
The FDA issued an updated Drug Safety Communication warning that co‑administration of Victrelis (boceprevir) with ritonavir‑boosted HIV protease inhibitors—atazanavir, darunavir, or lopinavir/ritonavir—is not recommended for patients co‑infected with hepatitis C and HIV. The interaction lowers blood concentrations of both drugs,...
The FDA added a safety warning to Revlimid (lenalidomide) after clinical trials showed a markedly higher incidence of second primary malignancies in newly diagnosed multiple myeloma patients. Pooled data revealed a three‑fold increase (7.9% vs 2.8%) in cancers such as...
